Annexon, Inc.
1400 Sierra Point Parkway
Building C Suite 200
Brisbane, CA 94005
United States
650 822 5500
https://www.annexonbio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 71
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Douglas Love Esq., J.D. | CEO, President & Director | 980.12k | 無 | 1968 |
| Dr. Dean R. Artis Ph.D. | Chief Scientific Officer & Executive VP | 797.38k | 無 | 1961 |
| Dr. Ted Yednock Ph.D. | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 697.76k | 無 | 1958 |
| Ms. Jennifer Lew | Executive VP, CFO & Corporate Secretary | 624.2k | 無 | 1973 |
| Mr. Michael Overdorf M.B.A. | Executive VP & Chief Business Officer | 580.47k | 無 | 1971 |
| Henk-Andre Kroon M.D. | Senior Vice President of Translational Medicine | 無 | 無 | 無 |
| Dr. Jamie Dananberg M.D. | Executive VP & Chief Medical Officer | 無 | 無 | 1958 |
描述
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
公司管治
截至 2024年5月1日 止，Annexon, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：3；董事會：6；股東權利：8；現金賠償：9。
